International Journal of Head and Neck Surgery

Register      Login

VOLUME 13 , ISSUE 1 ( January-March, 2022 ) > List of Articles

INVITED REVIEW ARTICLE

Recurrent Respiratory Papillomatosis: An Update

Abdullah Alanazi, Anatoli F Karas, Inna A Husain

Keywords : Bevacizumab, Cidofovir, HPV, HPV vaccine, Respiratory papillomatosis

Citation Information : Alanazi A, Karas AF, Husain IA. Recurrent Respiratory Papillomatosis: An Update. Int J Head Neck Surg 2022; 13 (1):1-7.

DOI: 10.5005/jp-journals-10001-1514

License: CC BY-NC 4.0

Published Online: 25-05-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

The aim of this article is to describe the pathogenesis, etiology, clinical course, prevention, and management of recurrent respiratory papillomatosis (RRP). RRP is a challenging chronic disease of the respiratory tract that occurs in both children and adults. It is caused by human papillomavirus (HPV), with more than 90% caused by HPV 6 and HPV 11 types. While there is no definitive treatment for RRP, the goal of treatment focuses on improving voice quality and maintaining airway patency. The clinical presentation is nonspecific with the majority of patients presenting with hoarseness, stridor, or dyspnea. Surgical management is the mainstay of treatment of RRP, and about 20% of the patients benefit from adjuvant therapies including cidofovir, bevacizumab, interferon, and others. Prevention of the disease with the HPV vaccine and practicing safe sex may play a major role in decreasing the incidence of HPV infection and RRP.


PDF Share
  1. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995;121(12):1386–1391. DOI: 10.1001/archotol.1995.01890120044008
  2. Bauman NM, Smith RJH. Recurrent respiratory papillomatosis. Pediatr Clin North Am 1996:43(6):1385–1401. DOI: 10.1016/s0031-3955(05)70524-1
  3. Marchiori E, Neto CA, Meirelles GS, et al. Laryngotracheo-bronchial papillomatosis: findings on computed tomography scans of the chest. J Bras Pneumol 2008;34(12):1084–1089. DOI:10.1590/s1806-37132008001200016
  4. Cook TA, Cohen AM, Brunschwig JP, et al. Laryngeal papilloma: etiology and therapeutic considerations. Ann Otol Rhinol Laryngol 1973:82(5):649–655. DOI: 10.1177/000348947308200507
  5. Donne AJ, Hampson L, Homer JJ, et al. The role of HPV type in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2010;74(1):7–14. DOI:10.1016/j.ijporl.2009.09.004
  6. Hoesli RC, Wingo ML, Richardson BE, et al. Identification of 11 different HPV subtypes in adult patients with recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2020;163(4):785–790. DOI: 10.1177/0194599820931817.
  7. Wiatrak BJ, Wiatrak DW, Broker TR, et al. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004;114(11 Pt 2 Suppl 104): 1–23. DOI: 10.1097/01.mlg.000148224.83491.0f
  8. Costa V, El-Achkar VN, de Barros PP, et al. Role of epstein-barr virus in the severity of recurrent respiratory papillomatosis. Laryngoscope 2020;130(11):E611–E618. DOI:10.1002/lary.28465
  9. Burchell AN, Winer RL, Sanjosé SD, et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006;24 Suppl 3:S3/52–61. DOI: 10.1016/j.vaccine.2006.05.031
  10. Fusconi M, Grasso M, Greco A, et al. Rrecurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta otorhinlaryngol ital 2014:34(6):375–381.
  11. Carifi M, Napolitano D, Morandi M, et al. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin risk Manag 2015;11:731–738. DOI: 10.2147/TCRM.S81825
  12. Quick CA, Watts SL, Krzyzek RA, et al. Relationship between condylomata and laryngeal papillomata. Ann Oto Rhinol Laryngo 1980;89(5 Pt 1):467–471. DOI: 10.1177/000348948008900521
  13. Abramson AL, Steinberg BM, Winkler B. Laryngeal papillomatosis: clinical histopathologic and molecular studies. Layngoscope 1987;97(6):678–685. DOI:10.1288/00005537-198706000-00005
  14. Venkatesan NN, Pine HS, Underbrink M, et al. Recurrent respiratory papillomatosis. Otolaryngologic Clin North Am 2012;45(3):671–694 viii-ix. DOI: 10.1016/j.otc.2012.03.006
  15. Derkay CS, Malis DJ, Zalzal G, et al. A staging system for assessing severity and response to therapy in recurrent respiratory papillomatosis. Larngoscope 1998;108(6):935–937. DOI: 10.1097/00005537-199806000-00026
  16. Prince JS, Duhamel DR, Levin DL, et al. Nonneoplastic lesions of the tracheobronchial wall: radiologic findings with bronchoscopic correlation. Radiographics 2002;22 Spec No: S215-S230. DOI: 10.1148/radiographics.22.suppl_1.g02oc02s215
  17. Lee JH, Smith RJ. Recurrent respiratory papillomatosis: pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg 2005;13(6): 354–359. DOI: 10.1097/01.moo.0000186205.91332.46
  18. Karatayli-Ozgursoy S, Avery Bishop J, Hillel A, et al. Risk factors for dysplasia in recurrent respiratory papillomatosis in an adult and pediatric population. Ann Otol Rhinol Laryngol 2016;125(3):235–241. DOI: 10.1177/0003489415608196
  19. Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006;91(8):689–691. DOI: 10.1136/adc.2005.090514
  20. Katsenos S, Becker H. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: a propos of two cases and a brief literature review. Case Rep Oncol 2011;4(1):162–171. DOI: 10.1159/000327094
  21. El-Bitar MA, Zalzal GH. Powered instrumentation in the treatment of recurrent respiratory papillomatosis: an alternative to the carbon dioxide laser. Arch Otolaryngol Head Neck Surg 2002;128(4):425–428. DOI: 10.1001/archotol.128.4.425
  22. Dedo HH, Yu KC. CO2 laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001;111(9):1639–1644. DOI: 10.1097/00005537-200109000-00028
  23. Zeitels SM, Burns JA. Laser applications in laryngology: past, present, and future. Otolaryngol Clin North Am 2006;39(1):159–172. DOI: 10.1016/j.otc.2005.10.001
  24. Crocket DM, McCabe BF, Shive CJ. Complications of laser surgery for recurrent respiratory papillomatosis, et al. Ann Otol Rhinol Laryngol 1987;96(6):639–644. DOI: 10.1177/000348948709600604
  25. Shah MD, Johns MM. Office-based laryngeal procedures. Otolaryngol Clin North Am 2013;46(1):75–84. DOI: 10.1016/j.otc.2012.08.019
  26. Yan Y, Olszewski AE, Hoffman MR, et al. Use of lasers in laryngeal surgery. J Voice 2010;24(1):102–109. DOI: 10.1016/j.jvoice.2008.09.006
  27. Rees CJ, Halum SL, Wijewickrama RC, et al. Patient tolerance of in-office pulsed dye laser treatments to the upper aerodigestive tract. Otolaryngol Head Neck Surg 2006;134(6):1023–1027. DOI: 10.1016/j.otohns.2006.01.019
  28. Miller AJ, Gardner GM. In-office vs. operating room procedures for recurrent respiratory papillomatosis. Ear Nose Throat J 2017;96(4-5): E24–E28. DOI:10.1177/0145561319889538
  29. Holler T, Allegro J, Chadha NK, et al. Voice outcomes following repeated surgical resection of laryngeal papillomata in children. Otolaryngol Head Neck Surg 2009;141(4):522–526. DOI: 10.1016/j.otohns.2009.06.080
  30. Ivancic R, Iqbal H, Silva BD et al. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2018;3(1):22–34. DOI: 10.1002/lio2.132
  31. Kashima HK, Mounts P, Leventhal B, et al. Sites of predilication in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 1933:102(8 Pt 1):580–583. DOI: 10.1177/000348949310200802
  32. Schraff S, Derkay CS, Burke B, et al. American Society of Pediatric Otolaryngology members’ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130(9):1039-1042. DOI: 10.1001/archotol.130.9.1039
  33. Pian Gi REAT, Ilmarinen T, van den Heuvel ER, et al. Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Eur Arch Otorhinolaryngol 2013;270(5):1679–1687. DOI: 10.1007/s00405-013-2358-7
  34. Coulombeau B, Nusa Naiman A, Ceruse P, et al. [Anti-viral injectable treatment (cidofovir) in laryngeal papillomatosis]. Rev Laryngol Otol Rhinol (Bord) 2002;123(5):315–320.
  35. Lee AS, Rosen CA. Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis. J Voice 2004;18(4):551–556. DOI: 10.1016/j.jvoice.2003.07.007
  36. Hoesli RC, Thatcher AL, et al. Evaluation of safety of intralesional cidofovir for adjuvant treatment of recurrent respiratory papillomatosis. JAMA Otolaryngology Head Neck Surg 2020;146(3):231–236. DOI: 10.1001/jamaoto.2019.4029
  37. Nodarse-Cuni H, Iznaga-Marin N, Viera-Alvarez D, et al. Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994–1999 report). J Laryngol Otol 2004;118(9):681–687. DOI: 10.1258/0022215042244741
  38. Szeps M, Dahlgren L, Aaltonen LM, et al. Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alspha interferon treatment. J of Gen Virol 2005;86(Pt 6): 1695–1702. DOI: 10.1099/vir.0.80849-0
  39. Zeitels SM, Barbu AM, Landau-Zemer T, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol 2011;120(10):627–634. DOI: 10.1177/000348941112001001
  40. Sidell DR, Nassar M, Cotton RT, et al. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2014;123(3):214–221. DOI: 10.1177/0003489414522977
  41. Tkaczuk A, Trivedi S, Mody MD, et al. Parenteral bevacizumab for the treatment of severe respiratory papillomatosis in an adult population. Laryngoscope 2021;131(3):E921–E928. DOI: 10.1002/lary.29133
  42. Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther 2018;182:152–160. DOI: 10.1016/j.pharmthera.2017.08.012
  43. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484–2496. DOI: 10.1056/NEJMoa1103799
  44. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596–604. DOI: 10.1093/jnci/djq091
  45. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027–1034. DOI: 10.1084/jem.192.7.1027
  46. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73(6):1733–1741. DOI: 10.1158/0008-5472.CAN-12-2384
  47. Hinrichs CS. Avelumab for people with recurrent respiratory papillomatosis. 2018. Available at: Clinicaltrials.gov. Accessed September 3, 2018
  48. Pai S. Pembrolizumab for HPV-associated recurrent respiratory papilloma patients with laryngeal, tracheal and/or pulmonary involvement. 2018. Available at: Clinicaltrials.gov. Accessed September 3, 2018
  49. Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 1982;73(suppl 1A):7–13. DOI: 10.1016/0002-9343(82)90055-9
  50. Chaturvedi J, Sreenivas V, Hemanth V, et al. Management of adult recurrent respiratory papillomatosis with oral acyclovir following micro laryngeal surgery: a case series. Indian J Otolaryngol Head Neck Surg 2014;66(Suppl 1):359–363. DOI: 10.1007/s12070-011-0456-7
  51. Aguado DL, Pifiero BP, Betancor L, et al. Acyclovir in the treatment of laryngeal papillomatosisis. International Journal of Pediatric Otorhinolaryngology 1991;21:269–274.
  52. Michnovicz JJ, Bradlow HL. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst 1990;82(11):947–949. DOI: 10.1093/jnci/82.11.947
  53. Rosen CA, Woodson GE, Thompson JW, et al. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1998;118(6):810–815. DOI: 10.1016/S0194-5998(98)70274-8
  54. Wilcox LJ, Hull BP, Baldassari CM, et al. Diagnosis and management of recurrent respiratory papillomatosis. Pediatr Infect Dis J 2014;33(12):1283–1284. DOI: 10.1097/INF.0000000000000551
  55. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J Voice 2015;29(2): 223–229. DOI: 10.1016/j.jvoice.2014.08.003
  56. Yiu Y, Fayson S, Smith H, et al. Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2019;128(4):309–315. DOI: 10.1177/0003489418821695
  57. Dion GR, Teng S, Boyd LR, et al. Adjuvant human papillomavirus vaccination for secondary prevention: a systematicreview. JAMA Otolaryngol Head Neck Surg 2017;143(6):614–622. DOI: 10.1001/jamaoto.2016.4736
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.